These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29464673)

  • 41. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.
    Eriksson I; Komen J; Piehl F; Malmström RE; Wettermark B; von Euler M
    Eur J Clin Pharmacol; 2018 May; 74(5):663-670. PubMed ID: 29429031
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis.
    Li P; Ladage VP; Berger J; Chahin S; Jhaveri M; Geremakis C; Doshi JA
    Value Health; 2020 Mar; 23(3):328-334. PubMed ID: 32197728
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database.
    Kawachi I; Okamoto S; Sakamoto M; Ohta H; Nakamura Y; Iwasaki K; Yoshida M; Hiroi S; Ogino M
    BMC Neurol; 2019 Dec; 19(1):324. PubMed ID: 31842786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Indirect impact of the COVID-19 pandemic on the care and outcomes of people with MS: A combined survey and insurance claims study.
    Meltzer E; Charron O; Wozny J; Onuorah H; Montague A; Kline AC; Largent A; Krause TM; Freeman L
    Mult Scler Relat Disord; 2023 Dec; 80():105085. PubMed ID: 37931487
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medication adherence/persistence among patients with active multiple sclerosis in Finland.
    Lahdenperä S; Soilu-Hänninen M; Kuusisto HM; Atula S; Junnila J; Berglund A
    Acta Neurol Scand; 2020 Dec; 142(6):605-612. PubMed ID: 32559310
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.
    Yermakov S; Davis M; Calnan M; Fay M; Cox-Buckley B; Sarda S; Duh MS; Iyer R
    J Med Econ; 2015; 18(9):711-20. PubMed ID: 25903661
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health care resource utilization and disease modifying treatment use in multiple sclerosis patients by age and insurance type.
    Cisternas M; Bartolome L; Gitar B; Hulbert E; Trenz H; Patel V; Johnson K; Russo PA
    Curr Med Res Opin; 2021 Apr; 37(4):597-604. PubMed ID: 33535846
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
    Ha-Vinh P; Nauleau S; Clementz M; Régnard P; Sauze L; Clavaud H
    Presse Med; 2019 Jan; 48(1 Pt 1):e1-e19. PubMed ID: 30528148
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of Switching to Fingolimod Versus Injectable Disease-Modifying Therapy Cycling on Risk of Multiple Sclerosis-Related Relapses: A Retrospective Analysis.
    Vieira MC; Li Y; Meng X; Zhou H; Piao OW; Kutz C; Conway D
    Int J MS Care; 2021; 23(2):73-78. PubMed ID: 33880083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study.
    Moccia M; Affinito G; Marrazzo G; Ciarambino T; Di Procolo P; Confalonieri L; Carotenuto A; Petracca M; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
    Neurol Int; 2024 Mar; 16(2):394-405. PubMed ID: 38668126
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk of cancer among Finnish multiple sclerosis patients.
    Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M
    Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis].
    Shmidt TE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):140-145. PubMed ID: 29265100
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
    Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
    J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.
    Setayeshgar S; Kingwell E; Zhu F; Zhang X; Zhang T; Marrie RA; Carruthers R; Tremlett H
    Mult Scler Relat Disord; 2018 Oct; 25():57-60. PubMed ID: 30036855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosis.
    Brandes DW; Raimundo K; Agashivala N; Kim E
    J Med Econ; 2013; 16(4):547-51. PubMed ID: 23391123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.